X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA AUROBINDO PHARMA NATCO PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 27.3 18.1 150.9% View Chart
P/BV x 20.7 5.9 351.9% View Chart
Dividend Yield % 0.6 0.4 156.9%  

Financials

 NATCO PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
AUROBINDO PHARMA
Mar-16
NATCO PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs8771,541 56.9%   
Low Rs424582 72.8%   
Sales per share (Unadj.) Rs223.4237.5 94.1%  
Earnings per share (Unadj.) Rs31.133.9 91.7%  
Cash flow per share (Unadj.) Rs40.340.6 99.2%  
Dividends per share (Unadj.) Rs5.002.50 200.0%  
Dividend yield (eoy) %0.80.2 326.4%  
Book value per share (Unadj.) Rs219.5120.6 182.0%  
Shares outstanding (eoy) m33.07585.17 5.7%   
Bonus/Rights/Conversions PAPREF-  
Price / Sales ratio x2.94.5 65.1%   
Avg P/E ratio x20.931.3 66.8%  
P/CF ratio (eoy) x16.126.2 61.7%  
Price / Book Value ratio x3.08.8 33.7%  
Dividend payout %16.17.4 218.0%   
Avg Mkt Cap Rs m21,504621,041 3.5%   
No. of employees `000NA13.3 0.0%   
Total wages/salary Rs m1,12815,508 7.3%   
Avg. sales/employee Rs ThNM10,457.6-  
Avg. wages/employee Rs ThNM1,167.1-  
Avg. net profit/employee Rs ThNM1,491.6-  
INCOME DATA
Net Sales Rs m7,389138,961 5.3%  
Other income Rs m1671,663 10.0%   
Total revenues Rs m7,556140,624 5.4%   
Gross profit Rs m1,79332,056 5.6%  
Depreciation Rs m3043,926 7.8%   
Interest Rs m3662,568 14.3%   
Profit before tax Rs m1,29027,225 4.7%   
Minority Interest Rs m4639 118.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3097,444 4.1%   
Profit after tax Rs m1,02719,820 5.2%  
Gross profit margin %24.323.1 105.2%  
Effective tax rate %23.927.3 87.5%   
Net profit margin %13.914.3 97.5%  
BALANCE SHEET DATA
Current assets Rs m3,681100,015 3.7%   
Current liabilities Rs m3,12374,759 4.2%   
Net working cap to sales %7.618.2 41.6%  
Current ratio x1.21.3 88.1%  
Inventory Days Days89107 83.3%  
Debtors Days Days59110 53.6%  
Net fixed assets Rs m7,68552,350 14.7%   
Share capital Rs m331585 56.5%   
"Free" reserves Rs m6,67067,707 9.9%   
Net worth Rs m7,25970,567 10.3%   
Long term debt Rs m9558,472 11.3%   
Total assets Rs m11,957156,994 7.6%  
Interest coverage x4.511.6 39.0%   
Debt to equity ratio x0.10.1 109.6%  
Sales to assets ratio x0.60.9 69.8%   
Return on assets %11.714.3 81.7%  
Return on equity %14.228.1 50.4%  
Return on capital %20.737.7 54.9%  
Exports to sales %39.451.0 77.1%   
Imports to sales %5.718.8 30.2%   
Exports (fob) Rs m2,90870,927 4.1%   
Imports (cif) Rs m42126,193 1.6%   
Fx inflow Rs m3,44571,015 4.9%   
Fx outflow Rs m70328,799 2.4%   
Net fx Rs m2,74342,216 6.5%   
CASH FLOW
From Operations Rs m1,44017,596 8.2%  
From Investments Rs m-1,089-13,801 7.9%  
From Financial Activity Rs m-353-198 177.9%  
Net Cashflow Rs m-13,597 -0.0%  

Share Holding

Indian Promoters % 52.0 54.1 96.2%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 8.0 98.6%  
FIIs % 16.6 27.7 60.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.2 254.9%  
Shareholders   25,395 69,601 36.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  SUVEN LIFE  PLETHICO PHARMA  WOCKHARDT LTD.  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

World Stocks Mixed as Global Market Rally Loses Momentum(RoundUp)

Global financial markets ended the week on a mixed note. In the US, the Dow industrials ended the week down 0.4%, while the S&P 500 declined 0.1%.

Related Views on News

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

More Views on News

Most Popular

The Real Brave-hearts are Those Who Still Have Deposits in IDBI Bank(Vivek Kaul's Diary)

Nov 6, 2017

It makes no sense to continue banking with this bank.

'Buy and Hold Forever' Not The Best Investing Style After All(The 5 Minute Wrapup)

Nov 9, 2017

Even Buffett didn't always Buy and Hold forever. A look at Berkshire's 1992 and 2017 portfolios will tell you the story...

Large cap funds are more liquid(The Honest Truth)

Nov 6, 2017

Is the dangerous illiquidity risk in small-cap and mid-cap funds common to large-cap funds too?

You're Lucky You Missed Out on that IPO...(Smart Contrarian)

Nov 8, 2017

Here's how to profit from upcoming IPOs.

Your Last Chance to Trade ONLY the Best Stocks(Daily Profit Hunter)

Nov 11, 2017

Techno-Funda opportunities are knocking on your door. Are you ready to receive them?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 17, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS